Here are relevant reports on : nephroprotective-drugs-market
-
Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030
Global veterinary dermatology market valued at $18.59B in 2024, reached $20.11B in 2025, and is projected to grow at a robust 8.5% CAGR, hitting $ 30.31B by 2030. The major factors that are driving the market are expanding companion animal population and pet ownership, growing concerns about infectious zoonotic diseases, rising awareness initiatives by government and animal welfare organizations, and increased adoption of pet insurance and high animal healthcare expenditure.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User—Global Forecast to 2031
The global veterinary pharmaceuticals market, valued at USD 27.41 billion in 2025, stood at USD 28.98 billion in 2026 and is projected to advance at a resilient CAGR of 6.3% from 2026 to 2031, culminating in a forecasted valuation of USD 39.37 billion by the end of the period. The market growth is driven by rising pet ownership, increasing livestock production, and higher demand for disease management drugs. Expanding awareness of animal health, growing expenditure on companion animals, and advancements in anti-infectives, parasiticides, and dermatology treatments are further supporting steady market expansion across developed and emerging regions.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Skin Cancer Drugs Market by Type (Chemotherapy, Immunotherapy), Disease Indication (Melanoma, Basal and Squamous), Distribution Channel – Global Forecast to 2027
The global skin cancer drugs market is projected to reach USD ~6 billion by 2027 from USD 4 billion in 2022, at a CAGR of 9 % during the forecast period
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Antipsychotic Drugs Market by Therapeutic Class (First Generation, Second Generation, Third Generation), Drug (Aripiprazole, Brexipiprazole, Risperidone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Forecast to 2027
The global antipsychotic drugs market is projected to reach USD ~25 billion by 2027 from USD 14 billion in 2022, at a CAGR of 8% between 2022 and 2027.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Human Insulin Market By Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2020
The global human insulin market size is projected to grow at a CAGR of 8.1%. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of this market.
- Published: December 2015
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
